Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.

Pinal-Fernandez I, Mecoli CA, Casal-Dominguez M, Pak K, Hosono Y, Huapaya J, Huang W, Albayda J, Tiniakou E, Paik JJ, Johnson C, Danoff SK, Corse AM, Christopher-Stine L, Mammen AL.

Neurology. 2019 Oct 8. pii: 10.1212/WNL.0000000000008443. doi: 10.1212/WNL.0000000000008443. [Epub ahead of print]

PMID:
31594859
2.

Identification of distinctive interferon gene signatures in different types of myositis.

Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Paik J, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL.

Neurology. 2019 Sep 17;93(12):e1193-e1204. doi: 10.1212/WNL.0000000000008128. Epub 2019 Aug 21.

PMID:
31434690
3.

Myositis Autoantibodies: A Comparison of Results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot.

Mecoli CA, Casal-Dominguez M, Pak K, Pinal-Fernandez I, Albayda J, Tiniakou E, Paik JJ, Zahid U, Danoff SK, Mammen AL, Casciola-Rosen L, Christopher-Stine L.

Arthritis Rheumatol. 2019 Aug 20. doi: 10.1002/art.41088. [Epub ahead of print]

PMID:
31430029
4.

Sporadic inclusion body myositis: Diagnostic value of p62 immunostaining.

Milisenda JC, García AM, Jou C, Pinal-Fernandez I, O'Callaghan AS, Grau JM.

Med Clin (Barc). 2019 Jun 25. pii: S0025-7753(19)30350-1. doi: 10.1016/j.medcli.2019.04.022. [Epub ahead of print] English, Spanish.

PMID:
31253480
5.

Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ, Sanyal A, Mammen AL, Christopher-Stine L, Danoff SK.

Chest. 2019 Jun 22. pii: S0012-3692(19)31200-0. doi: 10.1016/j.chest.2019.05.023. [Epub ahead of print]

PMID:
31238042
6.

On using machine learning algorithms to define clinically meaningful patient subgroups.

Pinal-Fernandez I, Mammen AL.

Ann Rheum Dis. 2019 Jun 21. pii: annrheumdis-2019-215852. doi: 10.1136/annrheumdis-2019-215852. [Epub ahead of print] No abstract available.

PMID:
31227486
7.

Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al.

Sabbagh S, Pinal Fernandez I, Miller FW, Rider LG, Mammen AL.

Ann Rheum Dis. 2019 Jun 17. pii: annrheumdis-2019-215693. doi: 10.1136/annrheumdis-2019-215693. [Epub ahead of print] No abstract available.

PMID:
31208959
8.

Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease.

Huapaya JA, Hallowell R, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ, Lin CT, Hussien A, Mammen AL, Christopher-Stine L, Danoff SK.

Respir Med. 2019 Jul - Aug;154:6-11. doi: 10.1016/j.rmed.2019.05.012. Epub 2019 May 21.

PMID:
31176796
9.

Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome.

Casal-Dominguez M, Pinal-Fernandez I, Huapaya J, Albayda J, Paik JJ, Johnson C, Silhan L, Mammen AL, Danoff SK, Christopher-Stine L.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):858-861. Epub 2019 Apr 29.

10.

Amyloid-PET: a new tool for diagnosing IBM?

Pinal-Fernandez I, Mammen AL.

Nat Rev Rheumatol. 2019 Jun;15(6):321-322. doi: 10.1038/s41584-019-0223-9. No abstract available.

PMID:
31048779
11.

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.

Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.

Ann Rheum Dis. 2019 Jul;78(7):988-995. doi: 10.1136/annrheumdis-2018-215004. Epub 2019 Apr 24.

PMID:
31018961
12.

The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease.

Brusca RM, Pinal-Fernandez I, Psoter K, Paik JJ, Albayda J, Mecoli C, Tiniakou E, Mammen AL, Christopher-Stine L, Danoff S, Johnson C.

Respir Med. 2019 Apr;150:63-65. doi: 10.1016/j.rmed.2019.02.015. Epub 2019 Feb 21.

PMID:
30961952
13.

Myositis Autoantigen Expression Correlates With Muscle Regeneration but Not Autoantibody Specificity.

Pinal-Fernandez I, Amici DR, Parks CA, Derfoul A, Casal-Dominguez M, Pak K, Yeker R, Plotz P, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Paik JJ, Albayda J, Corse AM, Lloyd TE, Christopher-Stine L, Mammen AL.

Arthritis Rheumatol. 2019 Aug;71(8):1371-1376. doi: 10.1002/art.40883. Epub 2019 Jun 18.

PMID:
30861336
14.

Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies.

Casal-Dominguez M, Pinal-Fernandez I, Corse AM, Paik J, Albayda J, Casciola-Rosen L, Johnson C, Danoff SK, Christopher-Stine L, Tiniakou E, Mammen AL.

Neurology. 2019 Mar 26;92(13):e1416-e1426. doi: 10.1212/WNL.0000000000007188. Epub 2019 Mar 1.

PMID:
30824556
15.

Successful treatment of refractory mechanic's hands with ustekinumab in a patient with the antisynthetase syndrome.

Pinal-Fernandez I, Kroodsma CT, Mammen AL.

Rheumatology (Oxford). 2019 Jul 1;58(7):1307-1308. doi: 10.1093/rheumatology/kez020. No abstract available.

PMID:
30793759
16.

Corrigendum: Persistent upregulation of the β-tubulin tubb6, linked to muscle regeneration, is a source of microtubule disorganization in dystrophic muscle.

Randazzo D, Khalique U, Belanto JJ, Kenea A, Talsness DM, Olthoff JT, Tran MD, Zaal KJ, Pak K, Pinal-Fernandez I, Mammen AL, Sackett D, Ervasti JM, Ralston E.

Hum Mol Genet. 2019 Jun 1;28(11):1930. doi: 10.1093/hmg/ddz035. No abstract available.

17.

Correlation between quantitative and semiquantitative magnetic resonance imaging and histopathology findings in dermatomyositis.

Milisenda JC, Collado MV, Pinal-Fernandez I, Hormaza Jaramillo A, Faruch Bilfeld M, Cano MD, García AI, Tomás X, Grau JM.

Clin Exp Rheumatol. 2019 Jul-Aug;37(4):633-640. Epub 2018 Dec 19.

PMID:
30620292
18.

Persistent upregulation of the β-tubulin tubb6, linked to muscle regeneration, is a source of microtubule disorganization in dystrophic muscle.

Randazzo D, Khalique U, Belanto JJ, Kenea A, Talsness DM, Olthoff JT, Tran MD, Zaal KJ, Pak K, Pinal-Fernandez I, Mammen AL, Sackett D, Ervasti JM, Ralston E.

Hum Mol Genet. 2019 Apr 1;28(7):1117-1135. doi: 10.1093/hmg/ddy418. Erratum in: Hum Mol Genet. 2019 Jun 1;28(11):1930.

19.

Dermatomyositis etiopathogenesis: a rebel soldier in the muscle.

Pinal-Fernandez I, Mammen AL.

Curr Opin Rheumatol. 2018 Nov;30(6):623-629. doi: 10.1097/BOR.0000000000000540. Review.

PMID:
30148802
20.

Classification and management of adult inflammatory myopathies.

Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL.

Lancet Neurol. 2018 Sep;17(9):816-828. doi: 10.1016/S1474-4422(18)30254-0. Review.

PMID:
30129477
21.

Muscle endurance deficits in myositis patients despite normal manual muscle testing scores.

Amici DR, Pinal-Fernandez I, Pagkatipunan R, Mears A, de Lorenzo R, Tiniakou E, Albayda J, Paik JJ, Lloyd TE, Christopher-Stine L, Mammen AL, Chung T.

Muscle Nerve. 2019 Jan;59(1):70-75. doi: 10.1002/mus.26307. Epub 2018 Dec 18.

PMID:
30028529
22.

The diagnostic work-up of cancer-associated myositis.

Selva-O'Callaghan A, Martinez-Gómez X, Trallero-Araguás E, Pinal-Fernández I.

Curr Opin Rheumatol. 2018 Nov;30(6):630-636. doi: 10.1097/BOR.0000000000000535. Review.

PMID:
29965856
23.

Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.

De Lorenzo R, Pinal-Fernandez I, Huang W, Albayda J, Tiniakou E, Johnson C, Milisenda JC, Casal-Dominguez M, Corse AM, Danoff SK, Christopher-Stine L, Paik JJ, Mammen AL.

Neurology. 2018 Jun 5;90(23):e2068-e2076. doi: 10.1212/WNL.0000000000005638. Epub 2018 May 4.

24.

Immune-Mediated Necrotizing Myopathy.

Pinal-Fernandez I, Casal-Dominguez M, Mammen AL.

Curr Rheumatol Rep. 2018 Mar 26;20(4):21. doi: 10.1007/s11926-018-0732-6. Review.

25.

Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations.

Selva-O'Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, Trallero-Araguás E, Milisenda JC, Martínez MÁ, Marín A, Labrador-Horrillo M, Juárez C, Grau-Junyent JM.

Expert Rev Clin Immunol. 2018 Mar;14(3):215-224. doi: 10.1080/1744666X.2018.1440206. Epub 2018 Feb 23. Review.

26.

Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.

Fernández-Codina A, Pinilla B, Pinal-Fernández I, López C, Fraile-Rodríguez G, Fonseca-Aizpuru E, Carballo I, Brito-Zerón P, Feijóo-Massó C, López-Dupla M, Cid MC, Martínez-Valle F; Spanish Registry of IgG4 Related Disease (REERIGG4) investigators; Autoimmune Diseases Group (GEAS); Spanish Internal Medicine Society (SEMI).

Joint Bone Spine. 2018 Dec;85(6):721-726. doi: 10.1016/j.jbspin.2018.01.014. Epub 2018 Feb 13.

PMID:
29452298
27.

Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.

Yeker RM, Pinal-Fernandez I, Kishi T, Pak K, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.

Ann Rheum Dis. 2018 May;77(5):714-719. doi: 10.1136/annrheumdis-2017-212436. Epub 2018 Jan 23.

28.

Opportunistic infections in patients with idiopathic inflammatory myopathies.

Redondo-Benito A, Curran A, Villar-Gomez A, Trallero-Araguas E, Fernández-Codina A, Pinal-Fernandez I, Rodrigo-Pendás JÁ, Selva-O'Callaghan A.

Int J Rheum Dis. 2018 Feb;21(2):487-496. doi: 10.1111/1756-185X.13255. Epub 2018 Jan 5. Review.

PMID:
29314762
29.

Statins: pros and cons.

Pinal-Fernandez I, Casal-Dominguez M, Mammen AL.

Med Clin (Barc). 2018 May 23;150(10):398-402. doi: 10.1016/j.medcli.2017.11.030. Epub 2017 Dec 29. Review. English, Spanish.

30.

Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.

Pinal-Fernandez I, Ferrer-Fabregas B, Trallero-Araguas E, Balada E, Martínez MA, Milisenda JC, Aparicio-Español G, Labrador-Horrillo M, Garcia-Patos V, Grau-Junyent JM, Selva-O'Callaghan A.

Rheumatology (Oxford). 2018 Feb 1;57(2):388-396. doi: 10.1093/rheumatology/kex413.

31.

RIG-I expression in perifascicular myofibers is a reliable biomarker of dermatomyositis.

Suárez-Calvet X, Gallardo E, Pinal-Fernandez I, De Luna N, Lleixà C, Díaz-Manera J, Rojas-García R, Castellví I, Martínez MA, Grau JM, Selva-O'Callaghan A, Illa I.

Arthritis Res Ther. 2017 Jul 24;19(1):174. doi: 10.1186/s13075-017-1383-0.

32.

Lung transplantation in systemic sclerosis: A single center cohort study.

Fernández-Codina A, Berastegui C, Pinal-Fernández I, Silveira MG, López-Meseguer M, Monforte V, Guillén-Del Castillo A, Simeón-Aznar CP, Fonollosa-Plà V, Solé J, Bravo-Masgoret C, Román-Broto A.

Joint Bone Spine. 2018 Jan;85(1):79-84. doi: 10.1016/j.jbspin.2017.03.012. Epub 2017 Apr 11.

PMID:
28408277
33.

A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.

Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, Silhan L, Christopher-Stine L, Mammen AL, Danoff SK.

Rheumatology (Oxford). 2017 Jun 1;56(6):999-1007. doi: 10.1093/rheumatology/kex021.

34.

Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis.

Amici DR, Pinal-Fernandez I, Mázala DA, Lloyd TE, Corse AM, Christopher-Stine L, Mammen AL, Chin ER.

Acta Neuropathol Commun. 2017 Mar 22;5(1):24. doi: 10.1186/s40478-017-0427-7.

35.

Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.

Lloyd TE, Pinal-Fernandez I, Michelle EH, Christopher-Stine L, Pak K, Sacktor N, Mammen AL.

Neurology. 2017 Apr 11;88(15):1454-1460. doi: 10.1212/WNL.0000000000003821. Epub 2017 Mar 10.

36.

Mixed Connective Tissue Disease and Epitope Spreading: An Historical Cohort Study.

Escolà-Vergé L, Pinal-Fernandez I, Fernandez-Codina A, Callejas-Moraga EL, Espinosa J, Marin A, Labrador-Horrillo M, Selva-O'Callaghan A.

J Clin Rheumatol. 2017 Apr;23(3):155-159. doi: 10.1097/RHU.0000000000000500.

PMID:
28248800
37.

More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, Parks CA, Casciola-Rosen L, Christopher-Stine L, Mammen AL.

Rheumatology (Oxford). 2017 May 1;56(5):787-794. doi: 10.1093/rheumatology/kew470.

38.

Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.

Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1771-1776. doi: 10.1002/acr.23188.

39.

IgG4-related disease: Evidence from six recent cohorts.

Martínez-Valle F, Fernández-Codina A, Pinal-Fernández I, Orozco-Gálvez O, Vilardell-Tarrés M.

Autoimmun Rev. 2017 Feb;16(2):168-172. doi: 10.1016/j.autrev.2016.12.008. Epub 2016 Dec 15. Review.

PMID:
27988433
40.

High-resolution manometry in patients with idiopathic inflammatory myopathy: Elevated prevalence of esophageal involvement and differences according to autoantibody status and clinical subset.

Casal-Dominguez M, Pinal-Fernandez I, Mego M, Accarino A, Jubany L, Azpiroz F, Selva-O'callaghan A.

Muscle Nerve. 2017 Sep;56(3):386-392. doi: 10.1002/mus.25507. Epub 2017 Apr 4.

PMID:
27935079
41.

Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.

Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, Lahouti AH, Basharat P, Albayda J, Paik JJ, Ahlawat S, Danoff SK, Lloyd TE, Mammen AL, Christopher-Stine L.

Ann Rheum Dis. 2017 Apr;76(4):681-687. doi: 10.1136/annrheumdis-2016-210198. Epub 2016 Sep 20.

42.

Statin-associated autoimmune myopathy: A distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories.

Alvarado-Cardenas M, Marin-Sánchez A, Martínez MA, Martínez-Martínez L, Pinal-Fernandez I, Labrador-Horrillo M, Balada E, Mundet-Tuduri X, Gonzalez-Mera L, Casademont J, Acebes EM, Moreno PJ, Juarez C, Grau-Junyent JM, Pujol-Borrell R, Selva-O'Callaghan A.

Autoimmun Rev. 2016 Dec;15(12):1161-1166. doi: 10.1016/j.autrev.2016.09.005. Epub 2016 Sep 15. Review.

PMID:
27640317
43.

Spectrum of immune-mediated necrotizing myopathies and their treatments.

Pinal-Fernandez I, Mammen AL.

Curr Opin Rheumatol. 2016 Nov;28(6):619-24. doi: 10.1097/BOR.0000000000000335. Review.

PMID:
27607340
44.

Statin-Induced Anti-HMGCR-Associated Myopathy.

Basharat P, Lahouti AH, Paik JJ, Albayda J, Pinal-Fernandez I, Bichile T, Lloyd TE, Danoff SK, Casciola-Rosen L, Mammen AL, Christopher-Stine L.

J Am Coll Cardiol. 2016 Jul 12;68(2):234-5. doi: 10.1016/j.jacc.2016.04.037. No abstract available.

45.

Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.

Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, Christopher-Stine L, Danoff S.

Lung. 2016 Oct;194(5):733-7. doi: 10.1007/s00408-016-9896-x. Epub 2016 May 11.

PMID:
27166633
46.

Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.

Pinal-Fernandez I, Parks C, Werner JL, Albayda J, Paik J, Danoff SK, Casciola-Rosen L, Christopher-Stine L, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Feb;69(2):263-270. doi: 10.1002/acr.22920. Epub 2016 Dec 31.

47.

Fast 1.5 T chest MRI for the assessment of interstitial lung disease extent secondary to systemic sclerosis.

Pinal-Fernandez I, Pineda-Sanchez V, Pallisa-Nuñez E, Simeon-Aznar CP, Selva-O'Callaghan A, Fonollosa-Pla V, Vilardell-Tarres M.

Clin Rheumatol. 2016 Sep;35(9):2339-45. doi: 10.1007/s10067-016-3267-0. Epub 2016 Apr 23.

PMID:
27107755
48.

Erratum to: Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival.

Fernández-Codina A, Simeón-Aznar CP, Pinal-Fernandez I, Rodríguez-Palomares J, Pizzi MN, Hidalgo CE, Guillén-Del Castillo A, Prado-Galbarro FJ, Sarria-Santamera A, Fonollosa-Plà V, Vilardell-Tarrés M.

Rheumatol Int. 2017 Jan;37(1):177. doi: 10.1007/s00296-016-3470-y. No abstract available.

PMID:
27043027
49.

Cardiac involvement in systemic sclerosis: differences between clinical subsets and influence on survival.

Fernández-Codina A, Simeón-Aznar CP, Pinal-Fernandez I, Rodríguez-Palomares J, Pizzi MN, Hidalgo CE, Guillén-Del Castillo A, Prado-Galbarro FJ, Sarria-Santamera A, Fonollosa-Plà V, Vilardell-Tarrés M.

Rheumatol Int. 2017 Jan;37(1):75-84. doi: 10.1007/s00296-015-3382-2. Epub 2015 Oct 25. Erratum in: Rheumatol Int. 2017 Jan;37(1):177. Del Castillo, Alfredo Guillén [corrected to Guillén-Del Castillo, Alfredo].

PMID:
26497313
50.

Statins and myositis: the role of anti-HMGCR antibodies.

Selva-O'Callaghan A, Alvarado-Cardenas M, Marin A, Pinal-Fernandez I.

Expert Rev Clin Immunol. 2015;11(12):1277-9. doi: 10.1586/1744666X.2015.1102632. Epub 2015 Oct 22.

PMID:
26492593

Supplemental Content

Loading ...
Support Center